Literature DB >> 22030893

Cell-free fetal DNA in specimen from pregnant women is stable up to 5 days.

Sina P Müller1, Iris Bartels, Werner Stein, Günter Emons, Kai Gutensohn, Tobias J Legler.   

Abstract

OBJECTIVE: Before noninvasive prenatal diagnosis on the fetal Rhesus D status (NIPD RhD) can be implemented on a mass-scale, it is crucial to define requirements regarding sample transport. The aim of this study was to determine the relation between the transport time of samples for NIPD and the concentration of fetal DNA in maternal plasma.
METHOD: We analyzed qualitative and quantitative data obtained in a previous study performed with real-time PCR to determine the accuracy of NIPD RhD following two different DNA extraction protocols. The number of days from phlebotomy until freezing of plasma at the study site was recorded and defined as transport time.
RESULTS: NIPD RhD results of 972 specimens were analyzed according to transport time, which varied from a few hours to a maximum of 8 days (median 2 days). No decrease of cell-free fetal DNA was observed in samples with less than 6 days transport time. There was a pivotal trend to higher cycle threshold values in samples with ≥ 6 days transport time compared with those with ≤ 5 days.
CONCLUSION: Because only a few laboratories offer an NIPD RhD service, we suggest a maximal transport time of 5 days from phlebotomy until freezing at the testing laboratory.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030893     DOI: 10.1002/pd.2889

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  7 in total

1.  The Glass Slide Extraction System Snap Card Improves Non-Invasive Prenatal Genotyping in Pregnancies with Antibodies.

Authors:  Thomasz Adamczyk; Andrea Doescher; Paul V Haydock; Russ Aldrich; Eduard K Petershofen; Thomas H Müller
Journal:  Transfus Med Hemother       Date:  2015-10-26       Impact factor: 3.747

2.  Determination of Fetal RHD Genotype Including the RHD Pseudogene in Maternal Plasma.

Authors:  Karen Chinoca Ziza; Adolfo Wenjaw Liao; Marcia Dezan; Carla Luana Dinardo; Eduardo Jens; Rossana Pulcineli Vieira Francisco; Alfredo Mendrone Junior; Marcelo Zugaib; José Eduardo Levi
Journal:  J Clin Lab Anal       Date:  2016-09-06       Impact factor: 2.352

Review 3.  Potential of Next-Generation Sequencing in Noninvasive Fetal Molecular Blood Group Genotyping.

Authors:  Sandra Wienzek-Lischka; Sandy Bachmann; Vanessa Froehner; Gregor Bein
Journal:  Transfus Med Hemother       Date:  2020-01-20       Impact factor: 3.747

4.  Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma.

Authors:  Tadeja Dovč-Drnovšek; Polona Klemenc; Nataša Toplak; Tanja Blejec; Irena Bricl; Primož Rožman
Journal:  Transfus Med Hemother       Date:  2013-01-03       Impact factor: 3.747

5.  Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD.

Authors:  Frederik Banch Clausen; Tanja Roien Jakobsen; Klaus Rieneck; Grethe Risum Krog; Leif Kofoed Nielsen; Ann Tabor; Morten Hanefeld Dziegiel
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

6.  Quantification of cell-free DNA in normal and complicated pregnancies: overcoming biological and technical issues.

Authors:  Irina Manokhina; Tanjot K Singh; Maria S Peñaherrera; Wendy P Robinson
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

7.  Evaluation of sample stability and automated DNA extraction for fetal sex determination using cell-free fetal DNA in maternal plasma.

Authors:  Elena Ordoñez; Laura Rueda; M Paz Cañadas; Carme Fuster; Vincenzo Cirigliano
Journal:  Biomed Res Int       Date:  2013-10-07       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.